Legend Biotech Corp ADR (LEGN) Stock Price, Quote & News

Latest News on LEGN

Jan 7, 2025, 3:40 PM EST - 11 days ago

Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)

Dec 19, 2024, 8:01 AM EST - 4 weeks ago

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

$CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma$

Dec 9, 2024, 7:35 PM EST - 5 weeks ago

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Dec 5, 2024, 2:14 PM EST - 6 weeks ago

Legend Biotech: The Story Brightens

Nov 12, 2024, 2:45 PM EST - 2 months ago

Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:30 AM EST - 2 months ago

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 5, 2024, 9:10 AM EST - 2 months ago

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Nov 4, 2024, 7:30 AM EST - 2 months ago

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Oct 4, 2024, 8:00 AM EDT - 3 months ago

Stock Picks From Seeking Alpha's September 2024 New Analysts

AME CCL CRWD CUK DVN EGO EMR

Oct 3, 2024, 7:41 AM EDT - 3 months ago

Legend Biotech to set up new R&D facility in Philadelphia

Oct 3, 2024, 7:30 AM EDT - 3 months ago

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Sep 30, 2024, 9:47 AM EDT - 3 months ago

Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients

JNJ

Sep 27, 2024, 4:35 PM EDT - 4 months ago

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Sep 24, 2024, 9:00 AM EDT - 4 months ago

Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Sep 18, 2024, 6:39 AM EDT - 4 months ago

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Aug 20, 2024, 8:00 AM EDT - 5 months ago

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 9, 2024, 4:25 PM EDT - 5 months ago

Legend Biotech Corporation (LEGN) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 7:00 AM EDT - 5 months ago

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

Jul 26, 2024, 7:00 AM EDT - 6 months ago

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

Jul 10, 2024, 8:00 AM EDT - 6 months ago

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

Jun 17, 2024, 12:15 PM EDT - 7 months ago

Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst

Jun 3, 2024, 4:00 PM EDT - 8 months ago

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

May 29, 2024, 8:00 AM EDT - 8 months ago

Legend Biotech to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:00 PM EDT - 8 months ago

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

May 13, 2024, 12:13 PM EDT - 8 months ago

Legend Biotech Corporation (LEGN) Q1 2024 Earnings Call Transcript

May 13, 2024, 7:00 AM EDT - 8 months ago

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

$CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma$

Apr 22, 2024, 1:05 PM EDT - 9 months ago

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Apr 11, 2024, 8:00 AM EDT - 10 months ago

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results

Apr 5, 2024, 11:30 PM EDT - 10 months ago

Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

Mar 19, 2024, 8:30 AM EDT - 10 months ago

Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report

$CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma$

Mar 15, 2024, 3:15 PM EDT - 11 months ago

CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Mar 11, 2024, 12:09 PM EDT - 11 months ago

Legend Biotech Corporation (LEGN) Q4 2023 Earnings Call Transcript

Mar 11, 2024, 7:00 AM EDT - 11 months ago

Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights

$Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy$